Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
33 pending office actions • 19 art units • 31 examiners • 0 of 33 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 6 (18%) |
| §103 only | 4 (12%) |
| §102 only | 1 (3%) |
| §112 only | 3 (9%) |
| Double-patenting + other | 7 (21%) |
| Multi-statute (no §101) | 12 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRON, SEAN C | 2 | 53.0% | +30.8% |
| MOLOYE, TITILAYO | 2 | 62.5% | +47.9% |
| VARGAS MONTALVO, DIXOMARA | 1 | 92.5% | +8.5% |
| EDWARDS, MARK | 1 | 76.3% | +13.3% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.1% | +43.5% |
| KLINKEL, KORTNEY L | 1 | 39.5% | +43.7% |
| BAEK, JONGHWAN NMN | 1 | 60.0% | +0.0% |
| HILL, MYRON G | 1 | 66.3% | +20.4% |
| POPA, ILEANA | 1 | 21.4% | +15.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245281 | CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS | BUTTICE, AUDREY L | 119d overdue |
| 17973738 | DEVICES, SYSTEMS, AND METHODS FOR DIAGNOSING TREATING AND MONITORING CHRONIC PELVIC PAIN | TOTH, KAREN E | 91d overdue |
| 16971992 | TISSUE ANALYSIS BY MASS SPECTROMETRY | GODDARD, LAURA B | 71d overdue |
| 18301048 | TARGETING OF SRC-3 IN IMMUNE CELLS AS AN IMMUNOMODULATORY THERAPEUTIC FOR THE TREATMENT OF CANCER | DIBRINO, MARIANNE | 19d overdue |
| 17906490 | SARS-COV2-SPECIFIC T CELL COMPOSITIONS AND THEIR USE IN TREATING AND PREVENTING CORONAVIRUS AND OTHER RESPIRATORY VIRUS INFECTIONS | BARRON, SEAN C | 8d |
| 17995540 | DAILY LIVING MONITORING AND MANAGEMENT SYSTEM | EPPERT, LUCY CLARE | 20d |
| 18939178 | STEREOTACTIC PROCEDURE PLANNING FOR ROBOTIC SURGICAL PROCEDURES | VARGAS MONTALVO, DIXOMARA | — |
| 18856151 | COLLECTION PROBE AND METHODS OF USE THEREOF | EDWARDS, MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906490 | SARS-COV2-SPECIFIC T CELL COMPOSITIONS AND THEIR USE IN TREATING AND PREVENTING CORONAVIRUS AND OTHER RESPIRATORY VIRUS INFECTIONS | BARRON, SEAN C | 8d |
| 18856151 | COLLECTION PROBE AND METHODS OF USE THEREOF | EDWARDS, MARK | — |
| 18740824 | NKT-CELL SUBSET FOR IN VIVO PERSISTENCE AND THERAPEUTIC ACTIVITY AND PROPAGATION OF SAME | WEHBE, ANNE MARIE SABRINA | — |
| 18664964 | SMALL MOLECULE BTK DEGRADERS AND METHODS OF USE THEREOF | KLINKEL, KORTNEY L | — |
| 18576307 | RECOMBINANT MICROORGANISM-BASED METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASE | BARRON, SEAN C | — |
| 18282730 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | HILL, MYRON G | — |
| 18465333 | COMPOSITONS AND METHODS FOR USE OF KALIUM CHANNEL RHODOPSINS | POPA, ILEANA | — |
| 18449841 | Targeting the Tumor Microenvironment Using Manipulated NKT Cells | MOLOYE, TITILAYO | — |
| Art Unit | Apps |
|---|---|
| 1632 | 4 |
| 1653 | 2 |
| 1625 | 2 |
| 1641 | 2 |
| 3791 | 2 |
| 1634 | 2 |
| 1642 | 2 |
| 1618 | 1 |
| 1671 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18939178 | STEREOTACTIC PROCEDURE PLANNING FOR ROBOTIC SURGICAL PROCEDURES | VARGAS MONTALVO, DIXOMARA | — | §101§102 | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18856151 | COLLECTION PROBE AND METHODS OF USE THEREOF | EDWARDS, MARK | — | §102§112 | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18726702 | RXR AGONISTS IN EYE DISORDERS | INAM, SAHAR | — | §102§103§112 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18740824 | NKT-CELL SUBSET FOR IN VIVO PERSISTENCE AND THERAPEUTIC ACTIVITY AND PROPAGATION OF SAME | WEHBE, ANNE MARIE SABRINA | — | §102§103§112Other | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18664964 | SMALL MOLECULE BTK DEGRADERS AND METHODS OF USE THEREOF | KLINKEL, KORTNEY L | — | §102§103 | Non-Final OA | — | Pending | May 15, 2024 |
| 18576307 | RECOMBINANT MICROORGANISM-BASED METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASE | BARRON, SEAN C | 1653 | §103§112 | Non-Final OA | — | Pending | Jan 03, 2024 |
| 18570949 | METHODS FOR IN VIVO DELIVERY OF MICROBES TO HUMAN MICROENVIRONMENTS | BAEK, JONGHWAN NMN | 1618 | §102§103§112DP | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18282730 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | HILL, MYRON G | 1671 | §102§103§112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18465333 | COMPOSITONS AND METHODS FOR USE OF KALIUM CHANNEL RHODOPSINS | POPA, ILEANA | 1633 | §101§103§112 | Non-Final OA | — | Pending | Sep 12, 2023 |
| 18449841 | Targeting the Tumor Microenvironment Using Manipulated NKT Cells | MOLOYE, TITILAYO | 1632 | §112 | Final Rejection | — | Pending | Aug 15, 2023 |
| 18276164 | Engineered NKT Cells for Expansion and In Vivo Preservation and Methods of Use for the Control of Tumor Cells | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | 71d | Pending | Aug 07, 2023 |
| 18262037 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | RAO, PADMAJA S | 1627 | §102§112 | Non-Final OA | — | Pending | Jul 19, 2023 |
| 18267980 | DELIVERY OF ABETA VARIANTS FOR AGGREGATION INHIBITION | BERTOGLIO, VALARIE E | 1632 | §112DPOther | Final Rejection | — | Pending | Jun 16, 2023 |
| 18039661 | NOVEL RIPK1 KINASE TARGETING PROTACS AND METHODS OF USE THEREOF | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Final Rejection | 14d | Pending | May 31, 2023 |
| 18301048 | TARGETING OF SRC-3 IN IMMUNE CELLS AS AN IMMUNOMODULATORY THERAPEUTIC FOR THE TREATMENT OF CANCER | DIBRINO, MARIANNE | 1641 | §103§112 | Final Rejection | 19d overdue | Pending | Apr 14, 2023 |
| 18245281 | CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS | BUTTICE, AUDREY L | 1647 | §103§112 | Final Rejection | 119d overdue | Pending | Mar 14, 2023 |
| 18018552 | UNIVERSAL ANTIGEN-SPECIFIC T CELL BANKS AND METHODS OF MAKING AND USING THE SAME THERAPEUTICALLY | KELLY, ROBERT M | 1638 | §103 | Final Rejection | 16d | Pending | Jan 28, 2023 |
| 18017298 | VAGINAL STENT | DUBOSE, LAUREN | 3771 | §102§103§112 | Non-Final OA | — | Pending | Jan 20, 2023 |
| 18004194 | GENE THERAPY FOR STXBP1 ENCEPHALOPATHY | MOLOYE, TITILAYO | 1632 | §102§103 | Non-Final OA | — | Pending | Jan 04, 2023 |
| 17999408 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | RZECZYCKI, PHILLIP MATTHEW | 1625 | §102Other | Non-Final OA | — | Pending | Nov 21, 2022 |
| 17997161 | TREATMENT AND PREVENTION OF CANCER USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | CHATTIN, AMY MARIE | 1643 | §103DP | Non-Final OA | 73d overdue | Pending | Oct 26, 2022 |
| 17997171 | TREATMENT AND PREVENTION OF ALLOREACTIVITY USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | DAHLE, CHUN WU | 1641 | §112DP | Final Rejection | 3d overdue | Pending | Oct 26, 2022 |
| 17973738 | DEVICES, SYSTEMS, AND METHODS FOR DIAGNOSING TREATING AND MONITORING CHRONIC PELVIC PAIN | TOTH, KAREN E | 3791 | §101§112 | Non-Final OA | 91d overdue | Pending | Oct 26, 2022 |
| 17996759 | OVERCOMING THE TUMOR MICROENVIRONMENT FOR CELL THERAPY BY TARGETING MYELOID DERIVED SUPPRESSOR CELLS THROUGH A TRAIL-R2 SPECIFIC RECEPTOR | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | — | Pending | Oct 20, 2022 |
| 17995540 | DAILY LIVING MONITORING AND MANAGEMENT SYSTEM | EPPERT, LUCY CLARE | 3791 | §101§103§112 | Final Rejection | 20d | Pending | Oct 05, 2022 |
| 17907312 | TNFa SIGNALING TRIGGERS TUMOR-PROMOTING INFLAMMATION THAT CAN BE TARGETED TO THERAPY | KAUFMAN, CLAIRE M | 1674 | §112 | Final Rejection | — | Pending | Sep 26, 2022 |
| 17906490 | SARS-COV2-SPECIFIC T CELL COMPOSITIONS AND THEIR USE IN TREATING AND PREVENTING CORONAVIRUS AND OTHER RESPIRATORY VIRUS INFECTIONS | BARRON, SEAN C | 1653 | §101§102§103Other | Non-Final OA | 8d | Pending | Sep 16, 2022 |
| 17855322 | ADENOVIRAL- BASED BIOLOGICAL DELIVERY AND EXPRESSION SYSTEM FOR USE IN THE TREATMENT OF OSTEOARTHRITIS | MARVICH, MARIA | 1634 | §103§112DPOther | Non-Final OA | — | Pending | Jun 30, 2022 |
| 17756242 | SELECTIVE EXPANSION OF GENE-TARGETED CELLS | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103§112 | Final Rejection | — | Pending | May 19, 2022 |
| 17775203 | ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY | LU, CHENG | 1642 | §103§112DP | Final Rejection | — | Pending | May 06, 2022 |
| 17576597 | DENDRITIC CELL IMMUNOTHERAPY | JUEDES, AMY E | 1644 | §103§112DP | Non-Final OA | 132d overdue | Pending | Jan 14, 2022 |
| 17050341 | CAR T CELLS WITH ONE OR MORE INTERLEUKINS | CHASE, CAROL ANN | 1646 | §103 | Final Rejection | — | Pending | Oct 23, 2020 |
| 16971992 | TISSUE ANALYSIS BY MASS SPECTROMETRY | GODDARD, LAURA B | 1642 | §101§103 | Final Rejection | 71d overdue | Pending | Aug 21, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial